Detalles de la búsqueda
1.
Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
Rheumatology (Oxford)
; 62(11): 3601-3609, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36919768
2.
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Rheumatology (Oxford)
; 59(2): 292-302, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31312844
3.
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Ann Rheum Dis
; 76(3): 566-570, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27624791
4.
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
RMD Open
; 5(2): e000887, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31452928
5.
Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.
Rheumatol Ther
; 5(1): 231-242, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29209946
6.
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.
J Rheumatol
; 45(3): 405-410, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29093152
7.
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Arthritis Rheumatol
; 69(3): 506-517, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27723271
8.
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
BioDrugs
; 31(4): 357-367, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612179
9.
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
BioDrugs
; 31(4): 369-377, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600696
Resultados
1 -
9
de 9
1
Próxima >
>>